GIC joins consortium investing $570m in biotech firm I-Mab

The consortium was led by Hillhouse Capital Group.

Sovereign wealth fund GIC has joined a consortium of institutional investors to invest around $570.5m (US$418m) through a private in I-Mab, a China-headquartered clinic-stage biopharmaceutical company, according to a press release.

The consortium, led by Hillhouse Capital Group, also include Avidity Partners, OrbiMed, Octagon Capital Advisors, Invus, Lake Bleu Capital, Perceptive Advisors, Cormorant Asset Management, Sphera Healthcare and Alyeska Investment Group.

I-Mab reportedly plans to use the proceeds to fund its ongoing and planned research and clinical programmes, as well as to develop its commercialization capabilities in China.

If you've been wondering whether SBR could work for your company — yes, probably.

A lot of the companies we partner with started as readers. They'd been following our coverage for a while, saw their own customers and competitors in it, and eventually asked the obvious question: could we do something with you? The answer is usually yes. The shape of it depends on what you're trying to do.

The options are broader than most people assume — thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. Some partners use one channel; most use a mix. We figure out the right combination by starting with your brief, not with our rate card.

So if the question has been on your mind, here's the easy way to ask it.

We'll tell you honestly whether we can help, and how. It's a better use of everyone's time.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia